Just say NO to biofilms: NO-donors are used to disperse a bacterial biofilm so that co-administered antibiotics will kill the more susceptible unattached cells. The chemically stable cephalosporin-3'-diazeniumdiolate NO-donor prodrug is activated by bacterial β-lactamases and facilitates this two-step biofilm erradication.

The bulk nanostructures of a prototypical 'good' solvate ionic liquid (SIL) and 'poor' SIL have been examined using neutron diffraction and empirical potential structure refinement (EPSR) simulated fits. The good SIL formed by a 1 : 1 mixture of lithium bis(trifluoromethylsulfonyl)imide (Li[TFSI]) in tetraglyme (G4), denoted [Li(G4)][TFSI], and the poor SIL formed from a 1 : 1 mixture of lithium nitrate (Li[NO3]) in G4, denoted [Li(G4)][NO3], have been studied. In both SILs there are strong Lewis acid-base interactions between Li(+) and ligating O atoms. However, the O atoms coordinated to Li(+) depend strongly on the counter anion present. LiO coordination numbers with G4 are 2-3 times higher for [Li(G4)][TFSI] than [Li(G4)][NO3], and conversely the LiO anion coordination number is 2-3 times higher in [Li(G4)][NO3]. In both solvates the local packing of Li around G4 O atoms are identical but these interactions are less frequent in [Li(G4)][NO3]. In both SILs, Li(+) has a distribution of coordination numbers and a wide variety of different complex structures are present. For [Li(G4)][NO3], there is a significant proportion uncoordinated G4 in the bulk; ∼37% of glyme molecules have no LiO contacts and each G4 molecule coordinates to an average of 0.5 Li(+) cations. Conversely, in [Li(G4)][TFSI] only ∼5% of G4 molecules lack LiO contacts and G4 molecules coordinates to an average of 1.3 Li(+) cations. Li(+) and G4 form polynuclear complexes, of the form [Lix(G4)y](x+), in both solvates. For [Li(G4)][TFSI] ∼35% of Li(+) and G4 form 1 polynuclear complexes, while only ∼10% of Li(+) and G4 form polynuclear complexes in [Li(G4)][NO3].

Use of biofilm dispersing NO-donor compounds in combination with antibiotics has emerged as a promising new strategy for treating drug-resistant bacterial biofilm infections. This paper details the synthesis and preliminary evaluation of six cephalosporin-3'-diazeniumdiolates as biofilm-targeted NO-donor prodrugs. Each of the compounds is shown to selectively release NO following reaction with the bacteria-specific enzyme β-lactamase and to trigger dispersion of Pseudomonas aeruginosa biofilms in vitro.

PYRRO-C3D is a cephalosporin-3-diazeniumdiolate nitric oxide (NO) donor prodrug designed to selectively deliver NO to bacterial infection sites. The objective of this study was to assess the activity of PYRRO-C3D against nontypeable Haemophilus influenzae (NTHi) biofilms and examine the role of NO in reducing biofilm-associated antibiotic tolerance. The activity of PYRRO-C3D on in vitro NTHi biofilms was assessed through CFU enumeration and confocal microscopy. NO release measurements were performed using an ISO-NO probe. NTHi biofilms grown on primary ciliated respiratory epithelia at an air-liquid interface were used to investigate the effects of PYRRO-C3D in the presence of host tissue. Label-free liquid chromatography-mass spectrometry (LC/MS) proteomic analyses were performed to identify differentially expressed proteins following NO treatment. PYRRO-C3D specifically released NO in the presence of NTHi, while no evidence of spontaneous NO release was observed when the compound was exposed to primary epithelial cells. NTHi lacking ␤-lactamase activity failed to trigger NO release. Treatment significantly increased the susceptibility of in vitro NTHi biofilms to azithromycin, causing a log fold reduction (10-fold reduction or 1-log-unit reduction) in viability (P Ͻ 0.05) relative to azithromycin alone. The response was more pronounced for biofilms grown on primary respiratory epithelia, where a 2-log-unit reduction was observed (P Ͻ 0.01). Label-free proteomics showed that NO increased expression of 16 proteins involved in metabolic and transcriptional/translational functions. NO release from PYRRO-C3D enhances the efficacy of azithromycin against NTHi biofilms, putatively via modulation of NTHi metabolic activity. Adjunctive therapy with NO mediated through PYRRO-C3D represents a promising approach for reducing biofilm-associated antibiotic tolerance.